Concepedia
Statistics
Publications
6
Citations
258
H-Index
Active since
2002
Affiliations
The University of Sydney(Current)
Royal Prince Alfred Hospital
Peter Tobin is an author at The University of Sydney specializing in medicine, pharmacology, and drug design.
Top concepts
MedicinePharmacologyOncologyDrug DesignBiochemistryCancer TherapyDrug DiscoveryCancer ResearchDrug ResistancePeptide Science
Publications per year
2002–2005
Expression of multidrug transporter<i>MRP4/ABCC4</i>is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan<i>in vitro</i>
Murray D. Norris, Janice Smith, Kara M. Tanabe et al. · Molecular Cancer Therapeutics · 2005 · 136 citations · Full text
A pilot study on the safety of combining chrysin, a non-absorbable inducer of UGT1A1, and irinotecan (CPT-11) to treat metastatic colorectal cancer
Peter Tobin, Philip Beale, Leesa Noney et al. · Cancer Chemotherapy and Pharmacology · 2005 · 46 citations
Oncology, Non-absorbable Inducer, Medicine +8
The<i>in vitro</i>metabolism of irinotecan (CPT‐11) by carboxylesterase and β‐glucuronidase in human colorectal tumours
Peter Tobin, Stephen Clarke, J. Paul Seale et al. · British Journal of Clinical Pharmacology · 2005 · 33 citations · Full text
The relative contributions of carboxylesterase and β-glucuronidase in the formation of SN-38 in human colorectal tumours
Peter Tobin, Helen M. Dodds, Stephen Clarke et al. · Oncology Reports · 2003 · 17 citations
The Importance of Tumor Glucuronidase in the Activation of Irinotecan in a Mouse Xenograft Model
Helen M. Dodds, Peter Tobin, Clinton F. Stewart et al. · Journal of Pharmacology and Experimental Therapeutics · 2002 · 14 citations
1–5 of 6